Effect of Daily and Every Other Day Stereotactic Body Radiation Therapy Schedules on Treatment-Related Fatigue in Patients With Hepatocellular Carcinoma

Hasan, Shaakir; Renz, Paul; Packard, Matthew; Horrigan, Sean; Gresswell, Steven; Kirichenko, Alexander

doi:10.1016/j.prro.2018.06.005

Cited by 10 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results showing sustained high levels of fatigue after RT were not in line with earlier studies (Hasan et al, 2019; Klein et al, 2015). Specifically, the finding from a previous study indicating that fatigue levels can revert to baseline at the third and sixth months after RT contradicts our results (Klein et al, 2015).…”

Section: Discussioncontrasting

confidence: 99%

“…Identifying long-term changes in fatigue can help healthcare providers better understand the course of fatigue and inform the appropriate timing of nursing interventions. However, the change in fatigue over time in patients with liver cancer receiving RT has been investigated in only a few studies (Hasan et al, 2019; Klein et al, 2015), with the findings indicating that fatigue improves with time in most patients after completion of RT (Hasan et al, 2019; Klein et al, 2015) but remains high in those with poorer liver functions (Klein et al, 2015). Although the change of fatigue in patients with liver cancer receiving RT was explored in the abovementioned studies, none has examined how fatigue has changed from preradiation (baseline) through RT administration and into the posttreatment period.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Persistent Fatigue in Patients With Hepatocellular Carcinoma Receiving Radiotherapy

CHEN,

HUANG,

HONG

et al. 2024

Journal of Nursing Research

View full text Add to dashboard Cite

Background Radiation therapy has attracted much attention in the treatment of patients with hepatocellular carcinoma (HCC). However, the association between radiotherapy-related fatigue and HCC has been examined in only a few studies. Purpose This study was designed to explore the change over time in fatigue in patients with HCC treated with radiotherapy and related factors. Methods One hundred patients were enrolled in this prospective longitudinal study using convenience sampling at a medical center in northern Taiwan. The Functional Assessment of Chronic Illness Therapy-Fatigue scale, the Brief Pain Inventory-Short Form, and the psychological subscale of Memorial Symptom Assessment Scale-Short Form were used to assess the symptoms at five time points: before radiotherapy (T0), during treatment (T1), and at 1 month (T2), 3 months (T3), and 6 months (T4) after radiotherapy. The generalized estimating equations method was used to determine the changes in fatigue and the influencing factors. Results Fatigue levels at T1, T2, T3, and T4 were significantly higher than that at T0. Higher fatigue was significantly associated with lower income and poorer functional status. Having worse pain levels and psychological symptoms were both associated with higher fatigue. Conclusions/Implications for Practice The results indicate fatigue does not recover to the baseline (pretherapy) level by 6 months after radiotherapy. Thus, fatigue in patients with HCC receiving radiotherapy should be regularly and effectively assessed, and patients experiencing pain and psychological symptoms should be given greater attention from clinicians.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Persistent Fatigue in Patients With Hepatocellular Carcinoma Receiving Radiotherapy

CHEN,

HUANG,

HONG

et al. 2024

Journal of Nursing Research

View full text Add to dashboard Cite

show abstract

“…This BED dose corresponds to 50 Gy in 15 fractions, 36.7 Gy in seven fractions, and 35 Gy in five fractions as a treatment radiation dose. Protocols that extend the treatment duration, such as irradiation every alternate day, resulted in the reduction of adverse events, such as rectal toxicity in prostate cancer, carotid blowout syndrome in recurrent head and neck cancer, and general fatigue in hepatocellular carcinoma, after SBRT treatment [18][19][20].…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Facial Merkel Cell Carcinoma Using CyberKnife Radiotherapy Alone: A Case Report

Mizumatsu,

Fujiyama

2023

Cureus

View full text Add to dashboard Cite

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine skin tumor. Herein, we present a case of MCC which was successfully treated with radiotherapy alone using CyberKnife® (CK) (Accuray Incorporated, Sunnyvale, California, United States). An 86-year-old female patient presented with multiple painless pink rash skin tumors on the left cheek. The patient was diagnosed with MCC based on a lesion biopsy (T2cN2M0, stage IIIB). The patient was referred for CK radiotherapy (CKR) at our institution because of her advanced age and inoperative lesions. The patient underwent CKR alone, with a planning target volume (PTV) of 14.9 ml, a prescribed dose of 30 Gy, a maximum dose of 46.2 Gy, and an isodose line (the minimum dose of 95% of the PTV) of 65% in 10 fractions for 13 days. The lesions had completely regressed on the last day of CKR. Left cervical lymph node metastasis (CLNM) appeared 10 months after CKR. The patient underwent a second CKR for CLNM, the PTV was 4.6 ml, and the prescribed dose was 27 Gy in three fractions for three days. The CLNM had completely regressed one month later after the second CKR. Primary lesions did not recur for 33 months after the initial CKR, and CLNM did not reappear for 23 months after the second CKR with good cosmetic results. No CKR-related adverse event occurred in our follow-up period. Our present case indicates that CKR is an effective treatment option for patients with MCC, particularly elderly patients who may not be suitable candidates for extensive surgical resection.

show abstract

“…This BED dose corresponds to 50 Gy in 15 fractions, 36.7 Gy in seven fractions, and 35 Gy in five fractions as a treatment radiation dose. It has been reported that protocols with irradiation every alternate day resulted in the reduction of adverse events, such as rectal toxicity in prostate cancer, carotid blowout syndrome in recurrent head and neck cancer, and general fatigue in hepatocellular carcinoma after treatment with SBRT [10][11][12]. Kubicek et al [13] have reported that surgical complications and control rates were satisfactory with a regimen of 35-40 Gy in five fractions every alternate day as a preoperative RT for soft tissue sarcoma.…”

Section: Discussionmentioning

confidence: 99%

Treating Low-Grade Myxofibrosarcoma With Stereotactic Body Radiation Therapy Using CyberKnife®

Mizumatsu¹,

Ryu²,

Nomura³

et al. 2021

Cureus

View full text Add to dashboard Cite

Myxofibrosarcoma (MFS) is one of the most common soft tissue sarcomas. Low-grade MFS has a high local recurrence rate, similar to that of high-grade MFS. Hence, appropriate adjuvant therapy is required to control low-grade MFS. In this report, we present a case in which recurrent low-grade MFS was successfully treated with stereotactic body radiation therapy (SBRT) using CyberKnife® (CK) (Accuray Incorporated, Sunnyvale, CA). A 76-year-old man underwent SBRT using CK for recurrent low-grade MFS in the right posterior chest wall after undergoing resection and skin grafting four and three times, respectively. We planned CK treatment separately for each in two parts. For the lesion on the scapula side, the target volume was 109 cm 3 and the total prescribed dose was 34.6 Gy, while the lesion on the spinal side had a target volume of 72 cm 3 and a total prescribed dose of 36 Gy, both in five fractions. Each SBRT was performed on alternate days in a span of 14 days. The tumors gradually reduced in size with tolerable levels of toxicity. SBRT using CK could be a safe and effective adjuvant therapy for low-grade MFS.

show abstract

Effect of Daily and Every Other Day Stereotactic Body Radiation Therapy Schedules on Treatment-Related Fatigue in Patients With Hepatocellular Carcinoma

Cited by 10 publications

References 29 publications

Persistent Fatigue in Patients With Hepatocellular Carcinoma Receiving Radiotherapy

Persistent Fatigue in Patients With Hepatocellular Carcinoma Receiving Radiotherapy

Successful Treatment of Facial Merkel Cell Carcinoma Using CyberKnife Radiotherapy Alone: A Case Report

Treating Low-Grade Myxofibrosarcoma With Stereotactic Body Radiation Therapy Using CyberKnife®

Contact Info

Product

Resources

About